Compare Citius Pharmaceuticals Inc (CTXR) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while ProShares UltraPro Short QQQ ETF trades at $32.93 (market cap $2.23B). The key difference: ProShares UltraPro Short QQQ ETF is far larger — about 163.7× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 60,436,012). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| CTXR | SQQQ | |
|---|---|---|
Market Cap | $13.62M | $2.23B |
Volume | 132,438 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $89.43 |
52-Week Low | $0.48 | $31.83 |
Typical Hold Time | 17 Days | 12 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
SQQQ, the ProShares UltraPro Short QQQ ETF, is currently trading at $33.02, up 2.93% on the day. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral momentum. As a 3x leveraged inverse ETF designed to profit from Nasdaq 100 declines, SQQQ's performance is directly tied to technology sector weakness. Recent news highlights its potential role as a hedging tool against QQQ holdings during market downturns.
The outlook for SQQQ depends heavily on technology sector performance, with potential gains during Nasdaq 100 declines but significant decay risk during sustained rallies. Investors face substantial volatility risks due to daily rebalancing and compounding effects. Current market conditions suggest continued uncertainty for tech stocks, potentially supporting SQQQ's short-term appeal as a tactical hedge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
